文献速递浆细胞疾病造血干细胞移植与细胞治疗

BCMA特异性中枢记忆CD8+细胞毒性T淋巴细胞选择性靶向多发性骨髓瘤:在疫苗接种与过继免疫治疗中的应用

Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy.
PubMed 文献 · Leukemia · 2019-03-12

研究在新诊断多发性骨髓瘤患者(n=616)的CD138+肿瘤细胞上鉴定抗原,确认BCMA为关键骨髓瘤相关抗原。报告新型工程化肽BCMA72-80与BCMA54-62较天然肽对HLA-A2亲和力/稳定性改善,诱导功能性BCMA特异性CTL。异源BCMA72-80特异性CTL表现多功能Th1免疫活性,抗OX40或抗LAG-3处理可增强其免疫功能,主要由中枢记忆CTL介导。

要点

  • 在新诊断MM患者CD138+肿瘤细胞中确认BCMA为关键骨髓瘤相关抗原。
  • 新型工程化肽BCMA72-80与BCMA54-62较天然肽对HLA-A2亲和力/稳定性改善。
  • 异源BCMA72-80特异性CTL经抗OX40或抗LAG-3处理免疫功能增强,主要由中枢记忆CTL介导。

核心结论

  • 异源BCMA72-80肽可单独或联合抗LAG-3和/或抗OX40治疗,用于疫苗接种和/或过继免疫治疗策略,以在多发性骨髓瘤或其他表达BCMA的肿瘤患者中产生持久抗肿瘤免疫。

研究设计与样本

  • 研究在新诊断多发性骨髓瘤患者的CD138+肿瘤细胞上鉴定多种抗原,样本量为n=616。

主要发现

  • 在新诊断MM患者(n=616)的CD138+肿瘤细胞上鉴定多种抗原,并确认BCMA为关键骨髓瘤相关抗原。
  • 新型工程化肽BCMA72-80(YLMFLLRKI)和BCMA54-62(YILWTCLGL)较其天然肽对HLA-A2显示改善的亲和力/稳定性。
  • 异源BCMA72-80特异性CTL对MM表现多功能Th1特异性免疫活性(IFN-γ/IL-2/TNF-α产生、增殖、细胞毒性),与Tetramer+和记忆CD8+ CTL扩增相关。
  • 异源BCMA72-80特异性CTL经抗OX40(免疫激动剂)或抗LAG-3(检查点抑制剂)处理后免疫功能增加,主要由中枢记忆CTL介导。

临床怎么用

  • 作者认为,异源BCMA72-80肽可单独或联合抗LAG-3和/或抗OX40治疗,用于疫苗接种和/或过继免疫治疗策略,以在多发性骨髓瘤或其他表达BCMA的肿瘤患者中产生持久抗肿瘤免疫。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To expand the breadth and extent of current multiple myeloma (MM)-specific immunotherapy, we have identified various antigens on CD138+ tumor cells from newly diagnosed MM patients (n = 616) and confirmed B-cell maturation antigen (BCMA) as a key myeloma-associated antigen. The aim of this study is to target the BCMA, which promotes MM cell growth and survival, by generating BCMA-specific memory CD8+ CTL that mediate effective and long-lasting immunity against MM. Here we report the identification of novel engineered peptides specific to BCMA, BCMA72-80 (YLMFLLRKI), and BCMA54-62 (YILWTCLGL), which display improved affinity/stability to HLA-A2 compared to their native peptides and induce highly functional BCMA-specific CTL with increased activation (CD38, CD69) and co-stimulatory (CD40L, OX40, GITR) molecule expression. Importantly, the heteroclitic BCMA72-80 specific CTL demonstrated poly-functional Th1-specific immune activities [IFN-γ/IL-2/TNF-α production, proliferation, cytotoxicity] against MM, which were correlated with expansion of Tetramer+ and memory CD8+ CTL. Additionally, heteroclitic BCMA72-80 specific CTL treated with anti-OX40 (immune agonist) or anti-LAG-3 (checkpoint inhibitor) display increased immune function, mainly by central memory CTL. These results provide the framework for clinical application of heteroclitic BCMA72-80 peptide, alone and in combination with anti-LAG3 and/or anti-OX40 therapy, in vaccination and/or adoptive immunotherapeutic strategies to generate long-lasting anti-tumor immunity in patients with MM or other BCMA expressing tumors.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Bae J, Samur M, Richardson P, et al. Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy. Leukemia. 2019. PMID: 30872779. doi:10.1038/s41375-019-0414-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。